Cohen et al. conducted a test to compare KRAS mutation in both ctDNA and protein LB biomarkers (AFP, CA15-3, CEA, CA-125, etc.)from 221 pancreatic cancer patients and 182 control patients [258]. Here, KRAS is linked to pancreatic neoplasm.